An empirical pipeline for personalized diagnosis of Lafora disease mutations
M. Kathryn Brewer,
Maria Machio-Castello,
Rosa Viana,
Jeremiah L. Wayne,
Andrea Kuchtová,
Zoe R. Simmons,
Sarah Sternbach,
Sheng Li,
Maria Adelaida García-Gimeno,
Jose M. Serratosa,
Pascual Sanz,
Craig W. Vander Kooi,
Matthew S. Gentry
Affiliations
M. Kathryn Brewer
Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY 40536, USA; Lafora Epilepsy Cure Initiative, Epilepsy and Brain Metabolism Center, and Center for Structural Biology, University of Kentucky College of Medicine, Lexington, KY 40536, USA
Maria Machio-Castello
Neurology Laboratory and Epilepsy Unit, Department of Neurology, IIS Fundación Jiménez Díaz, UAM and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid 28040, Spain
Rosa Viana
Institute of Biomedicine of Valencia, CSIC and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia 46010, Spain
Jeremiah L. Wayne
Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY 40536, USA
Andrea Kuchtová
Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY 40536, USA
Zoe R. Simmons
Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY 40536, USA
Sarah Sternbach
Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY 40536, USA
Sheng Li
Department of Medicine, University of California at San Diego, La Jolla, CA 92093, USA
Maria Adelaida García-Gimeno
Department of Biotechnology, Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural (ETSIAMN), Polytechnic University of Valencia, 46022 Valencia, Spain
Jose M. Serratosa
Lafora Epilepsy Cure Initiative, Epilepsy and Brain Metabolism Center, and Center for Structural Biology, University of Kentucky College of Medicine, Lexington, KY 40536, USA; Neurology Laboratory and Epilepsy Unit, Department of Neurology, IIS Fundación Jiménez Díaz, UAM and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid 28040, Spain
Pascual Sanz
Lafora Epilepsy Cure Initiative, Epilepsy and Brain Metabolism Center, and Center for Structural Biology, University of Kentucky College of Medicine, Lexington, KY 40536, USA; Institute of Biomedicine of Valencia, CSIC and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia 46010, Spain
Craig W. Vander Kooi
Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY 40536, USA; Lafora Epilepsy Cure Initiative, Epilepsy and Brain Metabolism Center, and Center for Structural Biology, University of Kentucky College of Medicine, Lexington, KY 40536, USA
Matthew S. Gentry
Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY 40536, USA; Lafora Epilepsy Cure Initiative, Epilepsy and Brain Metabolism Center, and Center for Structural Biology, University of Kentucky College of Medicine, Lexington, KY 40536, USA; Corresponding author
Summary: Lafora disease (LD) is a fatal childhood dementia characterized by progressive myoclonic epilepsy manifesting in the teenage years, rapid neurological decline, and death typically within ten years of onset. Mutations in either EPM2A, encoding the glycogen phosphatase laforin, or EPM2B, encoding the E3 ligase malin, cause LD. Whole exome sequencing has revealed many EPM2A variants associated with late-onset or slower disease progression. We established an empirical pipeline for characterizing the functional consequences of laforin missense mutations in vitro using complementary biochemical approaches. Analysis of 26 mutations revealed distinct functional classes associated with different outcomes that were supported by clinical cases. For example, F321C and G279C mutations have attenuated functional defects and are associated with slow progression. This pipeline enabled rapid characterization and classification of newly identified EPM2A mutations, providing clinicians and researchers genetic information to guide treatment of LD patients.